Dublin, Ireland, June 8, 2015 – Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced that Darren Cunningham, Chief Executive Officer, will present at the BIO International Convention in Philadelphia on Tuesday, June 16, 2015. The presentation will take place during the Oncology Track at 11:30 AM ET in Theatre 4 at the Pennsylvania Convention Center.
The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. 15,000 attendees from 65 countries are expected to participate in this year's event. For more information, please visit:http://convention.bio.org/.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-301 (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com